Butterfly Network, the Connecticut-based maker of handheld, whole-body ultrasound probes, announced on March 30, 2026 that it had received U.S. Food and Drug Administration clearance for a fully automated Gestational Age Tool built into its point-of-care ultrasound platform. The company describes it as the first FDA-cleared blind-sweep ultrasound AI tool for estimating how far along a pregnancy is, a routine but clinically important measurement that normally requires a trained sonographer and a dedicated ultrasound machine.
How the Blind-Sweep Method Works
Traditional gestational-age dating relies on a sonographer identifying specific fetal landmarks, such as head circumference or femur length, and manually measuring them on-screen. Butterfly’s tool instead uses a deep-learning model to interpret a “blind sweep,” in which an operator with minimal ultrasound training moves the probe across the abdomen in a guided pattern without needing to locate or freeze specific anatomical images. The software estimates gestational age directly from that sweep in under two minutes, following a three-step process: entering fundal height, applying gel, and performing the guided sweeps. Butterfly says the model was trained on more than 21 million ultrasound images and produces estimates comparable to those of a trained sonographer for pregnancies between 16 and 37 weeks.
Why Gestational Dating Is a Bigger Problem Than It Sounds
Knowing how far along a pregnancy is affects nearly every downstream clinical decision, from timing inductions to deciding whether a preterm birth needs specialized neonatal care. In well-resourced settings with routine first-trimester ultrasounds, this is rarely a problem. But in rural U.S. counties where the nearest imaging center may be hours away, and in low- and middle-income countries where trained sonographers are scarce, many pregnant patients arrive at delivery with no reliable estimate of gestational age at all, forcing clinicians to guess based on physical exam or a patient’s recollection of her last period.
Early Deployment in Malawi and Uganda
Ahead of and following the FDA clearance, Butterfly has already deployed the tool in Malawi and Uganda, work made possible in part by a grant from the Gates Foundation, which has long funded maternal-health technology aimed at low-resource settings. The company has said it intends to expand into additional countries in Sub-Saharan Africa under an expedited regulatory pathway, framing the U.S. clearance as a springboard for broader international rollout rather than an endpoint. In the United States, Butterfly is positioning the tool for rural clinics and emergency departments, where clinicians may need a fast gestational-age estimate for a patient in active labor with no prior prenatal records.
What Clinicians and Researchers Say
Maternal-health researchers have generally welcomed AI-assisted ultrasound as a way to extend specialist-level assessment to non-specialist operators, echoing similar arguments made about AI in diabetic-retinopathy and dermatology screening. Obstetric imaging specialists note, however, that a blind-sweep gestational-age estimate is not a substitute for a full anatomy scan, which checks for structural abnormalities and requires a trained sonographer regardless of AI assistance. The tool is explicitly scoped to gestational-age estimation between 16 and 37 weeks, not general prenatal diagnosis, and Butterfly has been careful in its own materials to describe it as filling a specific gap rather than replacing comprehensive obstetric ultrasound.
Part of a Broader Push in AI-Assisted Obstetrics
The clearance lands amid a wider 2026 trend of AI moving into pregnancy care, including predictive models for preeclampsia and gestational diabetes and digital tracking platforms such as India’s government-run JANANI system, which logs pregnancy, delivery, and newborn-care events at a population level. Industry analysts covering maternal-health technology have described 2026 as the year AI ultrasound moved from research demonstrations into FDA-cleared, revenue-generating products, with Butterfly’s clearance frequently cited as the clearest example so far.
What Happens From Here
Butterfly’s near-term priority is scaling the Malawi and Uganda deployments while pursuing additional international clearances, alongside a U.S. push into rural health systems that are already receiving new federal investment through rural health transformation initiatives. The bigger open question, echoed by health-access researchers, is whether a two-minute AI ultrasound sweep can meaningfully close the maternal-mortality gap between well-resourced and under-resourced regions, or whether the larger barriers, workforce shortages, transportation, and clinic infrastructure, will continue to limit how much any single device can accomplish on its own. Butterfly’s answer, for now, is to keep expanding where the tool is deployed and let the clinical outcomes data accumulate from there.
